Biomarin Pharmaceutical (BMRN) Accumulated Expenses (2010 - 2019)

Biomarin Pharmaceutical's Accumulated Expenses history runs 10 years deep, the most recent figure standing at $46.1 million for Q1 2019.

• Quarterly Accumulated Expenses rose 285.56% year-over-year to $46.1 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $46.1 million (up 285.56% YoY) and the FY2018 annual result came in at $149.9 million, up 6.5% from the prior year.
• Accumulated Expenses was $46.1 million for Q1 2019 at Biomarin Pharmaceutical, down from $149.9 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $179.3 million in Q4 2015 and bottomed at $12.0 million in Q1 2018.
• A 5-year average of $87.2 million and a median of $80.6 million in 2017 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2015 — Accumulated Expenses soared 3541.23% — and 2018, when it slumped 80.24%.
• Biomarin Pharmaceutical's Accumulated Expenses stood at $179.3 million in 2015, then plunged by 39.18% to $109.0 million in 2016, then gained by 29.11% to $140.8 million in 2017, then gained by 6.5% to $149.9 million in 2018, then tumbled by 69.25% to $46.1 million in 2019.
• Business Quant data shows BMRN's Accumulated Expenses at $46.1 million in Q1 2019, $149.9 million in Q4 2018, and $177.4 million in Q3 2018.